XML 73 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements Of Cash Flows (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Cash flows from operating activities:      
Net Income $ 385,721 $ 39,133 $ (224,282)
Adjustments to reconcile net income to net cash provided by operating activities:      
Provision for credit losses 10,000 30,000 250,229
Net gain on sales of loans (98,223) (61,097) (61,920)
Net gain on sales of investments and MBS (23,835) (16,236) (25,744)
Net loss (gain) on mortgage servicing rights 216 6,179 (1,125)
Other than temporary impairment 6,819 [1] 0 [1] 0 [1]
Stock based compensation 3,130 3,363 3,181
Loss on OREO 247 16,628 26,664
Charge on prepayment of debt 35,342 0 11,296
Increase in cash surrender value of BOLI (8,401) (6,213) (7,307)
Depreciation and amortization 45,843 42,651 39,517
Deferred income tax provision (benefit) (291,880) 275 113
Change in:      
Accrued interest receivable 8,337 1,261 9,782
Prepaid expenses and other assets (24,098) (1,342) 23,807
Accrued interest payable (18,479) 5,316 (4,986)
Accrued expenses and other liabilities (29,548) 9,003 (4,249)
Proceeds from sales of loans originated for sale 2,728,418 2,076,393 2,485,664
Loans originated for sale (2,915,204) (2,043,236) (2,455,895)
Net cash provided by operating activities (126,499) 84,072 73,243
Cash flows from investing activities:      
Change in restricted cash (11,043) (4,948) (7,458)
Net change in loans (500,452) (285,736) 1,125,793
Proceeds from sales of loans 139,356 91,456 324,328
Purchase of investment securities (3,734) (10,357) (33,179)
Proceeds from maturities of investment securities 20,588 2,012 5,500
Proceeds from sale of investment securities 199,966 30,987 17,534
Purchase of MBS (287,849) (760,519) (2,325,488)
Principal payments received on MBS 613,809 533,851 608,776
Proceeds from sales of MBS 679,208 555,353 1,039,143
Proceeds from BOLI death benefits 3,714 1,187 0
Office properties and equipment, net (9,853) (15,881) (3,034)
Improvements and other changes to OREO (1,282) (5,613) (5,434)
Proceeds from sales of OREO 91,402 246,609 165,504
Net change in cash and cash equivalents from acquisitions 121,098 0 0
Net cash provided by investing activities 1,054,928 378,401 911,985
Cash flows from financing activities:      
Net change in deposits (745,620) (425,189) (864,183)
Advances from FHLB 545,000 0 538,050
Repayment of advances from FHLB (345,210) (1,519) (1,478,995)
Net change in short term repurchase agreements (18,896) 23,251 (16,634)
Payments under structured repurchase agreements (485,342) 0 0
Proceeds from stock issuance, net 661 0 683,334
Dividends paid (49,743) 0 0
Net cash used in financing activities (1,099,150) (403,457) (1,138,428)
Net change in cash and cash equivalents (170,721) 59,016 (153,200)
Cash and cash equivalents, beginning of period 470,599 411,583 564,783
Cash and cash equivalents, end of period 299,878 470,599 411,583
Cash paid (received) during the period for:      
Interest 102,868 103,781 166,092
Income taxes, net 44 (250) (49,342)
Noncash financing and investing activities:      
Foreclosed real estate acquired in settlement of loans 33,499 177,881 265,115
Preferred stock cash dividend accrued 0 0 10,350
Conversion of Preferred Stock into Common Stock 0 0 295,384
Conversion of Preferred Stock Accrued Dividend into Common Stock 0 0 19,865
Conversion of Treasury Warrant 0 0 3,669
Parent Company [Member]
      
Cash flows from operating activities:      
Net Income 385,721 39,133 (224,282)
Adjustments to reconcile net income to net cash used in operating activities (412,528) (42,051) 214,128
Change in:      
Net cash provided by operating activities (26,807) (2,918) (10,154)
Cash flows from investing activities:      
Net cash provided by investing activities 52,600 0 (650,000)
Cash flows from financing activities:      
Proceeds from stock issuance, net 3,791 0 683,334
Dividends paid (49,743) 0 0
Net cash used in financing activities (45,952) 0 683,334
Net change in cash and cash equivalents (20,159) (2,918) 23,180
Cash and cash equivalents, beginning of period 44,602 47,520 24,340
Cash and cash equivalents, end of period $ 24,443 $ 44,602 $ 47,520
[1] The other-than-temporary impairment recognized in earnings during 2012 did not have a portion recognized in accumulated other comprehensive income.